Schrödinger, Inc. (NASDAQ:SDGR) Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR – Get Rating) by 4.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 229,900 shares of the company’s stock after buying an additional 10,000 shares during the quarter. Renaissance Technologies LLC owned 0.32% of Schrödinger worth $5,743,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE boosted its position in Schrödinger by 69.2% in the 1st quarter. US Bancorp DE now owns 1,932 shares of the company’s stock valued at $66,000 after buying an additional 790 shares during the period. IFP Advisors Inc boosted its position in Schrödinger by 294.7% in the 3rd quarter. IFP Advisors Inc now owns 3,750 shares of the company’s stock valued at $107,000 after buying an additional 2,800 shares during the period. SG Americas Securities LLC boosted its position in Schrödinger by 19.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,993 shares of the company’s stock valued at $105,000 after buying an additional 657 shares during the period. Tower Research Capital LLC TRC boosted its position in Schrödinger by 240.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $160,000 after buying an additional 4,499 shares during the period. Finally, Capital Impact Advisors LLC purchased a new position in Schrödinger in the 2nd quarter valued at approximately $223,000. Hedge funds and other institutional investors own 68.70% of the company’s stock.

Schrödinger Price Performance

Shares of SDGR opened at $23.47 on Friday. Schrödinger, Inc. has a 1-year low of $15.85 and a 1-year high of $37.25. The stock has a market cap of $1.67 billion, a PE ratio of -11.18 and a beta of 1.02. The firm has a fifty day moving average price of $23.12 and a 200 day moving average price of $22.78.

Insider Buying and Selling at Schrödinger

In other news, CEO Ramy Farid sold 66,886 shares of the business’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $18.28, for a total transaction of $1,222,676.08. Following the transaction, the chief executive officer now directly owns 184,432 shares in the company, valued at $3,371,416.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SDGR shares. The Goldman Sachs Group started coverage on shares of Schrödinger in a research report on Monday, December 19th. They set a “neutral” rating and a $23.00 price objective for the company. Citigroup lifted their price objective on shares of Schrödinger from $48.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, January 31st. Piper Sandler lifted their price objective on shares of Schrödinger from $86.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, January 19th. Finally, BMO Capital Markets decreased their price objective on shares of Schrödinger from $83.00 to $78.00 and set an “outperform” rating for the company in a research report on Wednesday, March 1st. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.40.

About Schrödinger

(Get Rating)

Schrödinger, Inc, together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries.